Ralph Schiess worked for more than a decade in world-class academic institutions both in the US and Europe and gained over 10 years of experience in the diagnostic industry successfully developing products from scientific prototypes to commercial products. He is currently the founding CEO of ZH3D (Zurich Hub for Drug and Device Development) at the University of Zurich. He was CEO and co-founder of Proteomedix AG, a Swiss healthcare company with the mission to transform prostate cancer diagnosis, which was acquired by Onconetix in December 2023. Under his guidance, Proteomedix identified novel biomarker signatures with utility in prostate cancer diagnosis, prognosis and therapy management. He received his M.S. from the University of Zurich, followed by an internship at the Institute of System Biology in Seattle. Thereafter, he received a doctorate in Science from the Swiss Federal Institute of Technology.